Timber Pharmaceuticals, Inc. Stock Price, News & Analysis

Timber Pharmaceuticals has extended its agreement with AFT Pharmaceuticals, granting Desitin Arzneimittel GmbH exclusive license and supply rights for TMB-002 in Europe. This new agreement focuses on the treatment of facial angiofibromas related to Tuberous Sclerosis Complex (TSC). As a result, Timber will receive a significant percentage of economics from any licensing deals made by AFT in regions outside North America. The agreement aims to provide an alternative to oral rapamycin, a widely used treatment associated with systemic toxicity.

Timber Pharmaceuticals announced that 50% of patients have been randomized in the Phase 2b CONTROL trial evaluating TMB-001 for moderate to severe congenital ichthyosis (CI). This milestone reflects the urgent need for new treatments in rare dermatologic diseases, which currently lack approved therapies. The company has also secured the final $1.5 million tranche of an FDA grant dedicated to orphan product clinical trials. The CONTROL study aims to enroll 45 patients and assess the safety and efficacy of two TMB-001 concentrations, potentially allowing for broader usage of isotretinoin.

Timber Pharmaceuticals (TMBR) announced that CEO John Koconis will present a corporate overview at the virtual 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available for on-demand viewing starting March 9 at 7:00 AM EST. Koconis and CFO Joe Luchese will also hold one-on-one investor meetings during the event. Timber focuses on developing treatments for rare dermatologic diseases, with a current emphasis on non-systemic therapies for conditions like congenital ichthyosis and facial angiofibromas.

Timber Pharmaceuticals Appoints Dr. Alan Mendelsohn as Chief Medical Officer

Timber Pharmaceuticals (TMBR) has announced the appointment of Dr. Alan Mendelsohn as Chief Medical Officer, succeeding Amir Tavakkol. Dr. Mendelsohn brings over 20 years of experience in clinical development, including his recent role at Sun Pharmaceuticals. He aims to enhance the company’s efforts in developing treatments for rare dermatologic diseases like congenital ichthyosis and facial angiofibromas. The leadership change is expected to strengthen Timber's clinical strategy as it advances into important research phases.

Timber Pharmaceuticals (TMBR) announced on January 12, 2021, that the FDA granted orphan drug designation to TMB-003, a treatment for systemic sclerosis. Currently, no FDA-approved treatments exist for cutaneous symptoms associated with this condition. TMB-003, a locally delivered formulation of sitaxsentan, aims to improve patient quality of life by addressing collagen buildup while minimizing systemic risks. Timber plans to submit an Investigational New Drug application in 2022 as it progresses into clinical research.

Timber Pharmaceuticals has received a formal notice of allowance for its patent application covering isotretinoin composition (U.S. Patent Application No.: 15/772,456) from the USPTO. This patent protection supports the development of TMB-001, a topical isotretinoin therapy for moderate to severe congenital ichthyosis (CI). Timber is working on a clinical program with potential orphan drug exclusivity, backed by a $1.5 million FDA grant for ongoing Phase 2a and 2b trials, actively enrolling patients across 11 sites in the U.S. and Australia.

Timber Pharmaceuticals, NYSE American: TMBR, has announced a business update conference call for investors on December 17th at 11:00am EST. The call will feature CEO John Koconis and CFO Joe Lucchese, discussing the company’s focus on developing treatments for rare dermatologic diseases. The conference call can be accessed via dial-in or live webcast, with a replay available on their website. Timber specializes in non-systemic therapies for conditions such as congenital ichthyosis and localized scleroderma. The company emphasizes its investigational therapies' proven mechanisms and established safety profiles.

Timber Pharmaceuticals (TMBR) announced its participation in the 13th Annual LD Micro Main Event on December 15, 2020, at 10:40 AM EST. CEO John Koconis will present to a virtual audience, highlighting the company’s focus on treatments for rare dermatologic diseases. The event, known for its unique format of 10-minute presentations followed by Q&A sessions, aims to engage both executives and investors. This Main Event will be held on the Sequire Virtual Events platform, emphasizing innovative approaches to virtual conferences.

Timber Pharmaceuticals (TMBR) announced the signing of waiver agreements with institutional investors regarding its series A and series B warrants. Effective November 19, 2020, the agreements allow for a one-time reset of the number of underlying shares and the exercise price. The series A warrants' exercise price is now set at $1.16 per share, with 20,178,214 shares underlying them. The series B warrants hold 22,766,776 shares. CEO John Koconis expressed optimism about achieving strategic goals following this arrangement.